← Open Payments lookup

NPI 1487880050: Open Payments

NPI 1487880050. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.

See the full provider profile for registry, prescribing and billing details.

Industry payments (Sunshine Act)

Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.

$1,369 in 61 payments from 14 companies in 2025. Trend: 2023 $1,853 · 2024 $1,840 · 2025 $1,369

Food & beverage: $1,369
CompanyPaymentsAmount
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)13$420
Otsuka America Pharmaceutical, Inc.13$224
Alkermes, Inc.6$122
Vanda Pharmaceuticals Inc.4$84
Axsome Therapeutics, Inc.4$82
Takeda Pharmaceuticals U.S.A., Inc.3$75
ABBVIE INC.3$73
E.R. Squibb & Sons, L.L.C.3$57
Lundbeck LLC3$56
Janssen Pharmaceuticals, Inc3$56

Products named: CAPLYTA, REXULTI, ARISTADA, FANAPT, Auvelity, TRINTELLIX, VRAYLAR, COBENFY.